Interchange Capital Partners LLC lowered its stake in Johnson & Johnson (NYSE:JNJ - Free Report) by 88.5% during the second quarter, according to the company in its most recent filing with the SEC. The fund owned 548 shares of the company's stock after selling 4,200 shares during the period. Interchange Capital Partners LLC's holdings in Johnson & Johnson were worth $84,000 as of its most recent filing with the SEC.
Other institutional investors and hedge funds have also bought and sold shares of the company. Ellis Investment Partners LLC grew its position in shares of Johnson & Johnson by 0.7% during the 2nd quarter. Ellis Investment Partners LLC now owns 8,559 shares of the company's stock worth $1,307,000 after purchasing an additional 62 shares in the last quarter. Cypress Wealth Services LLC grew its position in shares of Johnson & Johnson by 0.9% during the 2nd quarter. Cypress Wealth Services LLC now owns 6,634 shares of the company's stock worth $1,013,000 after purchasing an additional 62 shares in the last quarter. Horizon Bancorp Inc. IN grew its position in shares of Johnson & Johnson by 11.2% during the 2nd quarter. Horizon Bancorp Inc. IN now owns 636 shares of the company's stock worth $97,000 after purchasing an additional 64 shares in the last quarter. Global Strategic Investment Solutions LLC grew its position in shares of Johnson & Johnson by 3.5% during the 2nd quarter. Global Strategic Investment Solutions LLC now owns 1,925 shares of the company's stock worth $294,000 after purchasing an additional 65 shares in the last quarter. Finally, JSF Financial LLC grew its position in shares of Johnson & Johnson by 2.2% during the 2nd quarter. JSF Financial LLC now owns 2,993 shares of the company's stock worth $457,000 after purchasing an additional 65 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company's stock.
Wall Street Analyst Weigh In
A number of research analysts have issued reports on the stock. Weiss Ratings upgraded shares of Johnson & Johnson from a "hold (c+)" rating to a "buy (b-)" rating in a research report on Wednesday, October 8th. Wall Street Zen upgraded shares of Johnson & Johnson from a "hold" rating to a "buy" rating in a research report on Saturday, September 13th. Morgan Stanley set a $190.00 price target on shares of Johnson & Johnson in a research report on Wednesday. JPMorgan Chase & Co. increased their price target on shares of Johnson & Johnson from $185.00 to $200.00 and gave the stock a "neutral" rating in a research report on Tuesday, September 16th. Finally, Royal Bank Of Canada reiterated an "outperform" rating and set a $209.00 price target on shares of Johnson & Johnson in a research report on Friday, October 10th. Two analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and eight have given a Hold rating to the company. According to MarketBeat.com, Johnson & Johnson currently has a consensus rating of "Moderate Buy" and a consensus target price of $199.59.
Check Out Our Latest Report on Johnson & Johnson
Insider Buying and Selling
In related news, EVP Jennifer L. Taubert sold 56,471 shares of the stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the transaction, the executive vice president owned 178,013 shares of the company's stock, valued at $31,652,491.53. This represents a 24.08% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.16% of the stock is currently owned by insiders.
Johnson & Johnson Price Performance
Shares of NYSE:JNJ opened at $193.27 on Friday. The company has a market cap of $465.45 billion, a price-to-earnings ratio of 18.65, a PEG ratio of 2.26 and a beta of 0.40. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. The firm has a 50 day simple moving average of $180.49 and a 200 day simple moving average of $164.80. Johnson & Johnson has a one year low of $140.68 and a one year high of $194.40.
Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. The business had revenue of $24.02 billion during the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 33.08%. Research analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.
Johnson & Johnson Announces Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th will be paid a $1.30 dividend. The ex-dividend date of this dividend is Tuesday, November 25th. This represents a $5.20 annualized dividend and a yield of 2.7%. Johnson & Johnson's dividend payout ratio is presently 55.61%.
About Johnson & Johnson
(
Free Report)
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Johnson & Johnson, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.
While Johnson & Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
